Premium
Screening with monoclonal anti‐Fy3 to provide blood for phenotype‐ matched transfusions for patients with sickle cell disease
Author(s) -
Sandler S. G.,
Mallory D. A.,
Wolfe J. S.,
Byrne P. C.,
Lucas D. M.
Publication year - 1997
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.1997.37497265339.x
Subject(s) - phenotype , economic shortage , monoclonal antibody , medicine , immunology , red blood cell , population , typing , monoclonal , disease , blood transfusion , antibody , biology , gene , genetics , linguistics , philosophy , environmental health , government (linguistics)
BACKGROUND: In the United States, there is a shortage of blood group phenotype‐matched red cells (RBCs) for patients with sickle cell disease (SCD). A protocol designed to supply phenotype‐matched RBCs for these patients by combining the recruitment of African American blood donors and automated testing of RBCs for these patients for the presumptive Fy(a‐b‐) phenotype using monoclonal anti‐Fy3 was evaluated. STUDY DESIGN AND METHODS: African American donors were recruited, to increase the likelihood of phenotype matches in the donor population. Samples of RBCs were tested for the presumptive Fy(a‐b‐) phenotype by using monoclonal anti‐Fy3 and an automated blood typing analyzer. RBCs confirmed to be Fy(a‐b‐) were retyped for selected Rh, MNS, Kell, Duffy, and Kidd blood system antigens. The extended phenotypes were matched with those of 41 SCD patients requiring transfusions. RESULTS: Of 8323 blood donations during the study, approximately 40 percent (3329) were made by African Americans. Approximately 22 percent (737) of African Americans were identified as Fy(a‐b‐) by this protocol and 12 percent (410) were phenotype matches for the 41 SCD patients. CONCLUSION: Combining the recruitment of African American blood donors and automated phenotyping using monoclonal anti‐Fy3 offers a practical, relatively low‐cost strategy for supplying phenotype‐matched RBCs for SCD patients. This protocol increases the options for addressing the shortage of phenotype‐matched RBCs for SCD patients.